Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain
Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
The objective of this study is to verify the superiority of 16 weeks of MT-5547 treatment to
placebo, as evidenced by the WOMAC pain score (the efficacy outcome measure), in patients
with osteoarthritis of the knee or hip. Additional objectives of the study are to investigate
the efficacy, safety, and pharmacokinetics of MT-5547 in long-term use.